Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone and Plaque Study
NCT00231387Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2002
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerosis and type 2 diabetes mellitus (T2DM) comparing Rosiglitazone with Placebo (2 arms). Primary endpoint: Change from baseline of the plaque total wall volume in the carotid artery at 52 Weeks. Started Sep 2002; status: completed.
02
Drugs
rosiglitazone
03
Conditions
atherosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00231387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231387.